Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir

NCT02647632 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

OTHER_GOV

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: Grazoprevir/Elbasvir
DRUG: Sofosbuvir
DRUG: Ribavirin

Sponsor

ANRS, Emerging Infectious Diseases